AZD6234

Phase 3Small molecule

AstraZeneca

AZD6234 is one of 133 small molecule programs targeting Obesity & Overweight. It is currently in Phase 3.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obesity & OverweightActive, not recruiting

Obesity or OverweightNot yet recruiting

Hepatic ImpairmentRecruiting

Weight LossActive, not recruiting

Type 2 DiabetesActive, not recruiting

OverweightActive, not recruiting

Obesity & OverweightPhase 2

Active, not recruiting

Obesity or OverweightPhase 3

Not yet recruiting

Hepatic ImpairmentPhase 1

Recruiting

Weight LossPhase 2

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

OverweightPhase 1

Active, not recruiting

Competition

Competitive Landscape

171 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

AZD6234

AstraZeneca

Phase 3

1 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

Routine Treatment

GSK

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hepatic Impairment

NCT07546760

Q2 2027

Phase 1Active, not recruiting

Study completion

NCT07220954

Q3 2027

Phase 1Recruiting

Study completion

NCT07013643

Q3 2028

Phase 3Recruiting

Obesity or Overweight

NCT07776509

Phase 3Not yet recruiting

Obesity or Overweight

NCT07784270

Clinical

Trials by Indication[1]

Obesity or Overweight4 trials

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07776509·500 enrolled

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07784725·2,500 enrolled

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07784270·1,500 enrolled

Show 1 more trial

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06595238·262 enrolled

Overweight2 trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06132841·104 enrolled

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05511025·54 enrolled

Type 2 Diabetes1 trial

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06851858·69 enrolled

Renal Impairment1 trial

Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06845813·24 enrolled

Weight loss1 trial

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06862791·377 enrolled

3 more indications

Hepatic Impairment1 trial

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07546760·28 enrolled

Obesity & Overweight1 trial

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07017179·14 enrolled

Unspecified2 trials

An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07013643·50 enrolled

A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07220954·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for AZD6234. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD6234 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD6234. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

AZD6234

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q3 2028

Trials by Indication[1]

Obesity or Overweight4 trials

Overweight2 trials

Type 2 Diabetes1 trial

Renal Impairment1 trial

Weight loss1 trial

Hepatic Impairment1 trial

Obesity & Overweight1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News